Your browser doesn't support javascript.
loading
An RNA-hydrolyzing recombinant minibody prevents both influenza A virus and coronavirus in co-infection models.
Luong, Quynh Xuan Thi; Hoang, Phuong Thi; Lee, Yongjun; Ayun, Ramadhani Qurrota; Na, Kyungho; Park, Seonhyeon; Lin, Chengmin; Ho, Phuong Thi; Lee, Taek-Kyun; Lee, Sukchan.
Afiliación
  • Luong QXT; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
  • Hoang PT; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
  • Lee Y; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
  • Ayun RQ; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
  • Na K; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
  • Park S; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
  • Lin C; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
  • Ho PT; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.
  • Lee TK; Ecological Risk Research Department, Korea Institute of Ocean Science & Technology, Geoje, 53201, Korea. tklee@kiost.ac.kr.
  • Lee S; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea. cell4u@skku.edu.
Sci Rep ; 14(1): 8472, 2024 04 11.
Article en En | MEDLINE | ID: mdl-38605110
ABSTRACT
With the lifting of COVID-19 non-pharmaceutical interventions, the resurgence of common viral respiratory infections was recorded in several countries worldwide. It facilitates viral co-infection, further burdens the already over-stretched healthcare systems. Racing to find co-infection-associated efficacy therapeutic agents need to be rapidly established. However, it has encountered numerous challenges that necessitate careful investigation. Here, we introduce a potential recombinant minibody-associated treatment, 3D8 single chain variable fragment (scFv), which has been developed as a broad-spectrum antiviral drug that acts via its nucleic acid catalytic and cell penetration abilities. In this research, we demonstrated that 3D8 scFv exerted antiviral activity simultaneously against both influenza A viruses (IAVs) and coronaviruses in three established co-infection models comprising two types of coronaviruses [beta coronavirus-human coronavirus OC43 (hCoV-OC43) and alpha coronavirus-porcine epidemic diarrhea virus (PEDV)] in Vero E6 cells, two IAVs [A/Puerto Rico/8/1934 H1N1 (H1N1/PR8) and A/X-31 (H3N2/X-31)] in MDCK cells, and a combination of coronavirus and IAV (hCoV-OC43 and adapted-H1N1) in Vero E6 cells by a statistically significant reduction in viral gene expression, proteins level, and approximately around 85%, 65%, and 80% of the progeny of 'hCoV-OC43-PEDV', 'H1N1/PR8-H3N2/X-31', and 'hCoV-OC43-adapted-H1N1', respectively, were decimated in the presence of 3D8 scFv. Taken together, we propose that 3D8 scFv is a promising broad-spectrum drug for treatment against RNA viruses in co-infection.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus de la Influenza A / Coronavirus Humano OC43 / Subtipo H1N1 del Virus de la Influenza A / Anticuerpos de Cadena Única / Coinfección Límite: Humans Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus de la Influenza A / Coronavirus Humano OC43 / Subtipo H1N1 del Virus de la Influenza A / Anticuerpos de Cadena Única / Coinfección Límite: Humans Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido